Page last updated: 2024-09-04

pomalidomide and etoposide

pomalidomide has been researched along with etoposide in 1 studies

Compound Research Comparison

Studies
(pomalidomide)
Trials
(pomalidomide)
Recent Studies (post-2010)
(pomalidomide)
Studies
(etoposide)
Trials
(etoposide)
Recent Studies (post-2010) (etoposide)
62312155218,3063,6934,900

Protein Interaction Comparison

ProteinTaxonomypomalidomide (IC50)etoposide (IC50)
nuclear receptor coactivator 1 isoform 1 [Homo sapiens]Homo sapiens (human)1.153
nuclear receptor coactivator 3 isoform aHomo sapiens (human)1.4284
Polyunsaturated fatty acid lipoxygenase ALOX15Oryctolagus cuniculus (rabbit)3.187
Caspase-3Homo sapiens (human)1
DNA topoisomerase 2-betaHomo sapiens (human)0.4299
Solute carrier organic anion transporter family member 1B3Homo sapiens (human)4.18

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Beck, R; Ellis, PM; Fandi, A; Jungnelius, U; Shepherd, FA; Zhang, J1

Trials

1 trial(s) available for pomalidomide and etoposide

ArticleYear
A phase I study of pomalidomide (CC-4047) in combination with cisplatin and etoposide in patients with extensive-stage small-cell lung cancer.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2013, Volume: 8, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Small Cell Lung Carcinoma; Survival Rate; Thalidomide

2013